#USA #Marietta #Airway Therapeutics #Zelpultide Alfa #Joe Todisco

Airway Therapeutics Welcomes Joe Todisco to Its Board of Directors

In a significant move aimed at bolstering its strategic vision and driving growth, Airway Therapeutics, Inc. has announced the appointment of Joe Todisco to its board of directors, effective April 13, 2026. Airway Therapeutics, a biopharmaceutical company in late-stage clinical development, specializes in novel biological therapies targeting respiratory, inflammatory, and infectious diseases.

Joe Todisco: A Leader in Biopharma

Joe Todisco brings to Airway Therapeutics over 20 years of leadership experience within the pharmaceutical and biotechnology sectors. His impressive track record spans business strategy, corporate development, and an entrepreneurial spirit that promises to bolster the company's mission. Currently serving as the chairman and CEO of CorMedix Inc., Todisco previously held multiple leadership roles at Amneal Pharmaceuticals, including chief commercial officer for Amneal Specialty and senior vice president of corporate development and international operations. He is also a co-founder and former CEO of Gemini Laboratories LLC, a specialty pharmaceutical company acquired by Amneal.

Dr. Marc Salzberg, chairman and CEO of Airway Therapeutics, expressed enthusiasm over Todisco's extensive background in building and scaling specialty pharma companies. He noted, "Joe's expertise in hospital product marketing and operational strategies will be invaluable as we advance Zelpultide alfa through late development and prepare for its market launch. His inclusion will add a wealth of experienced perspective as we continue to grow our company."

The Focus on Zelpultide alfa

Zelpultide alfa, the leading candidate from Airway Therapeutics, is currently in late-stage clinical development aimed at preventing bronchopulmonary dysplasia (BPD) in very preterm infants—an area that presently lacks approved preventative therapies. With a vision to redefine the prevention and treatment of respiratory diseases, Airway is advancing Zelpultide alfa not only for pediatric applications but also for broader uses across various age groups.

"This is a pivotal time for the organization, and I am eager to join the board of Airway to further its pipeline and strategic vision," remarked Todisco regarding his appointment. His enthusiasm for Airway's innovative approach, particularly its lead candidate, highlights the company’s potential to meet significant unmet medical needs, including BPD.

Beyond BPD: A Broader Impact

Airway Therapeutics is not only focused on BPD but also aims to enhance outcomes for at-risk patient populations across multiple disease territories with its platform biologic. The ambition is clear: to leverage the unique properties of Zelpultide alfa and expand its therapeutic reach. This aligns with Todisco's history of successful product commercialization in specialized pharmaceutical sectors.

With his academic background, which includes a bachelor’s degree in economics from Georgetown University and an MBA from Fordham Graduate School of Business, Todisco is well-equipped to contribute strategically to Airway’s future. His depth of experience will provide crucial insights as the company navigates the complex landscape of biopharmaceutical development.

The Path Ahead for Airway Therapeutics

As Airway Therapeutics embarks on this new chapter with Joe Todisco on board, the medical and investor communities eagerly anticipate the next steps for Zelpultide alfa and its potential impact on pediatric healthcare. The appointment underscores the company's commitment to bringing cutting-edge therapies to market, improving treatment paradigms for respiratory and inflammatory conditions.

For more details on Airway Therapeutics and its groundbreaking research and developments, visit Airway Therapeutics.